“Atrial Fibrillation Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Atrial Fibrillation market. A detailed picture of the Atrial Fibrillation pipeline landscape is provided, which includes the disease overview and Atrial Fibrillation treatment guidelines.
The assessment part of the report embraces in-depth Atrial Fibrillation commercial assessment and clinical assessment of the Atrial Fibrillation pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial Fibrillation collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia. AF is often associated with other chronic cardiovascular conditions, including hypertension and heart failure, and long-term AF can result in a significantly raised risk of stroke – an estimated 15% of all strokes are caused by AF, and it accounts for one-third of strokes in individuals aged 65 years or older.
As per Xu J et al., there are three primary forms of AF that have been categorized with regards to duration of episode. The first type is the intermittent or paroxysmal AF, which occurs spontaneously and generally resolves by itself or with treatment within 7 days.
Persistent AF is the sustained abnormal heart rhythm for more than 7 days even with treatment or direct current cardioversion, while permanent AF occurs when all means of treatment to restore normal heart rhythm have failed.
Request for sample pages for the report: https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight
Atrial Fibrillation Key Pharma Players involved:
1. Bristol-Myers Squibb
2. ARCA Biopharma
3. Omeicos Therapeutics GmbH
Table of contents:
1. Report Introduction
2. Atrial Fibrillation
3. Atrial Fibrillation Current Treatment Patterns
4. Atrial Fibrillation- DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Atrial Fibrillation Late Stage Products (Phase-III)
7. Atrial Fibrillation Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Atrial Fibrillation Discontinued Products
13. Atrial Fibrillation Product Profiles
14. Atrial Fibrillation Key Companies
15. Atrial Fibrillation Key Products
16. Dormant and Discontinued Products
17. Atrial Fibrillation Unmet Needs
18. Atrial Fibrillation Future Perspectives
19. Atrial Fibrillation Analyst Review
21. Report Methodology
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Key players, such as Bristol-Myers Squibb, ARCA Biopharma, Omeicos Therapeutics GmbH, and many others are developing therapies for the treatment of patients with AFI. Gencaro (ARCA biopharma), Apixaban (Bristol-Myers Squibb), along with several other compelling options in the clinical trials are expected to increase the market size of AF in the upcoming years. A major upcoming player, ARCA Biopharma, has recently submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) to facilitate the development of Gencaro as a genetically-targeted treatment for heart failure (HF) patients at risk for Atrial Fibrillation.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States